TIVICAY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(3 years from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8129385 (Pediatric) | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(3 years from now) | |
|
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(6 years from now) | |
Tivicay is owned by Viiv Hlthcare.
Tivicay contains Dolutegravir Sodium.
Tivicay has a total of 4 drug patents out of which 0 drug patents have expired.
Tivicay was authorised for market use on 09 June, 2016.
Tivicay is available in tablet;oral dosage forms.
Drug patent challenges can be filed against Tivicay from 12 August, 2017.
The generics of Tivicay are possible to be released after 08 June, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-758) | Nov 21, 2020 |
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| M(M-166) | Jul 30, 2018 |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 09 June, 2016
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of TIVICAY before it's drug patent expiration?
More Information on Dosage
TIVICAY family patents
